GOLDEN, Colo.--(BUSINESS WIRE)--PharmaJet ®, a company who has developed and commercialized an intradermal needle-free platform to more effectively administer drugs and biologics, today announced that ...

PharmaJet, a global leader in needle-free injection technology, today announced that its WHO-prequalified Tropis ID ...

PharmaJet ®, a company focused on improving the performance and outcomes of injectables through needle-free injection technology, announced that its partner, Brazilian Tuberculosis Research Network ...

GOLDEN, Colo.--(BUSINESS WIRE)--PharmaJet ®, the maker of innovative, needle-free injection technology, announced that their latest partnerships and research results will be presented at the World ...

PharmaJet has struck an agreement covering the use of its Tropis needle-free injection system in Nigeria, positioning vaccinators to deploy the technology in a project intended to tackle a poliovirus ...

PharmaJet® to Highlight the Benefits of Intradermal Needle-free Delivery and Expansion into the Self-Injection Pen Market at Upcoming PODD Conference PharmaJet will deliver two presentations on ...

Proprietary technology positioned to become the new standard of care in global drug delivery SANTA CLARA, Calif., Oct. 2, 2018 /PRNewswire/ -- Based on its recent analysis of the global drug delivery ...

The MarketWatch News Department was not involved in the creation of this content. -- PharmaJet's Needle-free intradermal (ID) injection device ("Tropis(R) ID") will be evaluated as delivery system for ...

PharmaJet’s Needle-free intradermal (ID) injection device ("Tropis ® ID") will be evaluated as delivery system for the tuberculin skin test (TST) in a clinical study conducted by REDE-TB. The study ...